Affimed (NASDAQ:AFMD) Given Consensus Recommendation of “Hold” by Analysts

Affimed (NASDAQ:AFMD) has earned an average recommendation of “Hold” from the six brokerages that are presently covering the stock, Marketbeat reports. Six investment analysts have rated the stock with a hold recommendation. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $3.62.

AFMD has been the subject of several analyst reports. HC Wainwright downgraded shares of Affimed from a “buy” rating to a “neutral” rating in a report on Wednesday, May 14th. Leerink Partnrs lowered Affimed from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 13th. Cantor Fitzgerald lowered Affimed from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, May 14th. Wells Fargo & Company reaffirmed an “equal weight” rating and issued a $0.10 price target (down previously from $11.00) on shares of Affimed in a report on Tuesday, May 13th. Finally, Leerink Partners reissued a “market perform” rating and set a $0.39 price objective (down previously from $5.00) on shares of Affimed in a report on Tuesday, May 13th.

Affimed Stock Performance

Affimed stock opened at $0.18 on Friday. The stock has a 50-day simple moving average of $0.49 and a 200 day simple moving average of $0.97. The company has a current ratio of 1.93, a quick ratio of 1.93 and a debt-to-equity ratio of 0.13. Affimed has a 52 week low of $0.07 and a 52 week high of $7.11.

Institutional Trading of Affimed

A hedge fund recently raised its stake in Affimed stock. Intellectus Partners LLC boosted its stake in shares of Affimed (NASDAQ:AFMD) by 34.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 126,414 shares of the biopharmaceutical company’s stock after acquiring an additional 32,053 shares during the quarter. Intellectus Partners LLC owned 0.79% of Affimed worth $150,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 30.82% of the stock is owned by hedge funds and other institutional investors.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.